KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Inventory (2016 - 2025)

Gilead Sciences (GILD) has disclosed Inventory for 17 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 3.74% year-over-year to $1.8 billion, compared with a TTM value of $1.8 billion through Dec 2025, up 3.74%, and an annual FY2025 reading of $1.8 billion, up 3.74% over the prior year.
  • Inventory was $1.8 billion for Q4 2025 at Gilead Sciences, down from $1.8 billion in the prior quarter.
  • Across five years, Inventory topped out at $2.0 billion in Q2 2024 and bottomed at $1.5 billion in Q3 2022.
  • Average Inventory over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2024.
  • The sharpest move saw Inventory skyrocketed 80.43% in 2021, then decreased 16.69% in 2022.
  • Year by year, Inventory stood at $1.6 billion in 2021, then dropped by 6.86% to $1.5 billion in 2022, then increased by 18.58% to $1.8 billion in 2023, then fell by 4.31% to $1.7 billion in 2024, then increased by 3.74% to $1.8 billion in 2025.
  • Business Quant data shows Inventory for GILD at $1.8 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.8 billion in Q2 2025.